Wayne Tilley

Research Interests

Cancer Cell Biology Cancer Therapy Cancer Biology and Clinical Oncology Innovative Therapeutics

Prof Wayne Tilley

Dame Roma Mitchell Professor of Cancer Research

School of Medicine

College of Health

Eligible to supervise Masters and PhD as Principal Supervisor - email supervisor to discuss availability.

Professor Wayne Tilley is the Director of the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL), Adelaide Medical School, the University of Adelaide. His research career has spanned some 40 years in Australia, the USA and the UK, and has led to international acclaim as a world expert in the field of nuclear receptors and hormonal carcinogenesis. Professor Tilley’s research has an emphasis on mechanisms of sex hormone signalling and the emergence of resistance to hormonal therapies used in the treatment of breast and prostate cancer. He is internationally recognised for discoveries on steroid hormone receptor action, in particular androgen receptor (AR) structure and function (including cloning the human androgen receptor in the late 1980’s at UT Southwestern Medical School, Dallas TX) and AR function in breast and prostate cancers. He was one of the first to describe perturbations in AR signalling critical to progression of prostate cancer, including evidence for the oncogenic potential of the AR. Most recently, his research has provided evidence that the AR is a tumour suppressor in estrogen receptor (ER)-positive breast cancer and that the progesterone receptor (PR) can inhibit ER action in human breast cancer tissues by a novel reprograming mechanism (Nature 2015; Nature Medicine 2021). This research has led to 4 clinical trials of AR and PR activation in ER-driven disease.Professor Tilley’s research is unique in leveraging similarities in breast and prostate cancer to forge new insights into disease mechanisms and novel treatment strategies. Research in the DRMCRL uses contemporary genomic techniques and unique patient-derived model (PDEs, PDXs) systems to gain a deeper understanding into how sex hormones and their receptors control tumour behaviour. This information is used to develop new treatment strategies, with a clear view to improving patient outcomes.Professor Tilley’s research has attracted significant funding from government, non-government and philanthropic sources. He has published over 225 peer-reviewed papers. In 2016 he received the Endocrine Society of Australia Senior Plenary Award and gave the introductory Plenary Lecture at the 2016 International Congress of Endocrinology in Beijing, China. He was Chair of the 2015 Gordon Research Conference on Hormone-Dependent Cancers and a co-chair of the recent Fusion Nuclear Receptor Meeting in Mexico (4-7 May, 2022). Professor Tilley convenes the International PacRim Breast and Prostate Cancer Meeting Series.

 

The Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) have an international reputation for research into sex hormone action in hormone-dependent cancers, with a particular emphasis on breast and prostate cancers.

This world-class cancer research centre brings together expertise spanning more than 30 years in basic and translational prostate and breast cancer research. It is the leading centre in Australia with a multidisciplinary team of scientists, clinicians and patient advocates dedicated to understanding how sex hormones and their receptors control tumour behaviour in both disease contexts. The information is used to understand mechanisms of resistance to existing hormonal therapies for breast and prostate cancer and in developing new strategies for disease treatment and management. Research programs span discovery, drug development and clinical translation.

A major research focus at the DRMCRL is the development of novel androgen receptor (AR) and progesterone receptor (PR) targeted therapies for breast and prostate cancer. In prostate cancer, this involves the generation of drugs to inhibit aberrant forms of the AR that drive the disease and are unresponsive to conventional androgen deprivation therapies. In the case of breast cancer, our research has led to new strategies to activate the AR or PR to inhibit growth of tumours that are driven by the estrogen receptor (ER), as well as interrogation of Selective Androgen Receptor Modulators (SARMs), which have the ability to reprogram oncogenic AR activation in ER negative breast cancer.

Our laboratory has pioneered integration of genomic technologies with unique preclinical models of human breast and prostate cancers, especially patient-derived explant cultures and xenograft models, to better understand disease mechanisms and facilitate translation of breast and prostate cancer research into the clinic.

We publish in high impact journals such as Nature, Nature Genetics, Nature Reviews Cancer, Cancer Research, Clinical Cancer Research and Oncogene. Our research is well supported by funding from nationally and internationally competitive grants. The DRMCRL offers students a wide array of projects that span cutting-edge biomedical research using contemporary pre-clinical models, genome-wide technologies and access to large proteomic/genomic databases.

We are currently actively seeking students interested in bioinformatics to interrogate these databases, with opportunities of cross faculty supervision in fields such as mathematics and machine learning.

 

Key Research Projects Available for DRMCRL

Project 1 - Transforming endocrine therapy for breast and prostate cancer

Description -  Breast and prostate cancers are diseases driven by abnormal sex hormone receptor activity mediated by the estrogen receptor (ER) in breast and the androgen receptor (AR) in prostate cancers. Surgery and radiation therapy for these diseases work well when the tumour is confined within the organ of origin. However, for cancers that have spread out of the breast or prostate, either locally or to other parts of the body, the major treatment strategy is to completely abolish the activity of the offending sex hormone receptor. This treatment strategy is called hormone deprivation therapy and has been employed for the past century. Overwhelming evidence indicates that hormone deprivation therapy has run its course in providing a survival advantage to people with breast or prostate cancer.

Our hypothesis is that reprogramming estrogen or androgen receptors (ER and AR) away from oncogenic activity toward more benign activity will transform endocrine therapy for breast and prostate cancer. In this project we aim to discover optimal strategies to reprogram ER or AR activity in breast and prostate cancer by investigating three complementary approaches to reprogramming ER/AR: 1) Activate other nuclear receptors that directly inhibit ER/AR signalling; 2) Utilize selective ER/AR ligands; and 3) Enhance ER/AR reprogramming with epigenetic drugs. We will then validate optimal reprogramming strategies in patient-derived xenograft “clinical trials” and clinical samples.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

 

Project 2 - Selective activation of androgen receptor to treat estrogen receptor positive breast cancer

Description - Androgens, acting via the androgen receptor (AR), a protein related to the estrogen receptor (ER), are natural inhibitors of estrogen-stimulated breast cancer growth. Although androgens are commonly considered to be male hormones, females produce androgens throughout their life. AR typically is present in the same cells as ER, resulting in estrogen and androgen hormones exerting opposing forces on the growth of ER-positive breast cancers, with estrogen having growth promoting and androgens protective effects.



The goals of this project are: 1) Investigate how stimulation of the androgen receptor (AR) by a synthetic androgen which has been shown to be well tolerated by women, inhibits the growth of estrogen-sensitive breast tumours; and 2)  Develop and evaluate proteins identified as being potential biomarkers of response to androgenic therapies.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

 

Project 3 -  The clinical significance of sex hormone crosstalk in estrogen receptor positive breast cancer

Description - Breast cancer is mainly a disease in which the sex hormone estrogen stimulates uncontrolled growth via the estrogen receptor (ER). We have recently discovered that other sex hormones, including progesterone and androgen, can redirect the actions of estrogen in breast cancers to halt growth or make a tumour disappear. This project will examine the complex interaction between all three sex hormones to develop new, more effective strategies for treating breast cancer.

In this project, we will investigate the three-way interplay between ER, PR (progesterone receptor) and AR (androgen receptor) in contemporary models of breast cancer including patient derived xenografts and ex-vivo cultured primary tumour tissues. The ultimate goal is to determine clinical scenarios in which PR, AR or both could be optimally therapeutically targeted to treat ER+ breast cancer, particularly disease resistant to current ER targeting drugs.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

 

Project 4 - Pushing AR toward better outcomes in breast and prostate cancers

Description - This project will establish the efficacy of drugs called SARMs (selective androgen receptor modulators) for re-activating the normal, non-oncogenic function of the AR (androgen receptor) in human-derived pre-clinical models and clinical samples of breast and prostate cancers. Currently available SARMs (eg Enobosarm) have excellent safety profiles, and are poised for rapid implementation into clinical trials. Through our collaborations with clinicians that currently run breast cancer and prostate cancer clinical trials, we have access to breast cancer and prostate cancer samples, and also an avenue to prepare them to quickly implement novel treatment strategies that arise from this project.

The aims of this project are: 1) Identify SARMs that reprogram AR from oncogenic to benign genomic loci in breast cancers and prostate cancers; 2) Identify proteins that mediate AR reprogramming in breast and prostate cancers; 3) Pre-clinically test selected SARMs with therapeutic potential; and 4) Determine the clinical scope for SARMs and candidate biomarkers derived during the project. 

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

 

Project 5 - Targeting CDK9 in triple negative and endocrine-resistant breast cancers

Description - Triple negative breast cancer (TNBC) is the worst form of breast cancer at diagnosis. Better treatments for these cancers is a critical unmet need. TNBC preferentially afflicts young women and those with mutations of the BRCA1 gene. Another very aggressive form of breast cancer is estrogen receptor (ER) driven cancer that becomes resistant to ER targeting therapies. Chemotherapy and more recently, CDK4/6 inhibitors are the only approved means of treating these cancers, but survival rates remain low.

This project focuses on these highly aggressive breast cancers that collectively cause the majority of breast cancer-related death.  Such cancers have phenomenal rates of growth, in part due to elevated transcriptional activation of oncogenes. In collaboration with a medicinal chemist (Prof Shudong Wang), we are testing new drugs that specifically target CDK9, a factor that can ramp up the transcriptional activity of RNA polymerase II.  The goals of this project are: 1) Demonstrate the efficacy of novel CDK9 inhibitors in a unique suite of patient-derived xenograft models of triple negative and endocrine-resistant breast cancer; 2) Identify cellular mediators of CDK9-targeted therapy in these disease subtypes; and 3) Test our CDK9 inhibitors in prospectively-collected patient derived explant tumours cultured ex vivo and evaluate a biomarker signature of treatment response.

Available for: Honours and HDR

Start Date: Semester 1 and 2 2023

 

Date Position Institution name
2014 - ongoing Visiting Professorship University of Turku
2012 - 2014 Visiting Scientist, Cancer Research UK Cambridge University
2006 - ongoing Co-Director Adelaide Prostate Cancer Research Centre
2002 - ongoing Director, Dame Roma Mitchell Cancer Research Laboratories The University of Adelaide
2001 - 2002 Visiting Fellow, Norris Comprehensive Cancer Center University of Southern California
1996 - 2001 Director, Flinders Cancer Centre Flinders University
1992 - 1998 NHMRC Senior Research Fellow Flinders University
1991 - 1992 NHMRC CJ Martin Fellow Flinders University
1989 - 1991 Visiting Fellow, Department of Internal Medicine University of Texas Southwestern Medical Center
1987 - 1989 NHMRC CJ Martin Fellow University of Texas Southwestern Medical Center
1983 - 1986 NHMRC Senior Research Officer, Department of Surgery Flinders University

Date Type Title Institution Name Country Amount
2016 Award 2016 Senior Plenary Award Endocrine Society of Australia Australia -
2015 Award Executive Dean’s Awards 2015 The University of Adelaide Australia -
2008 Award Ron Ross Award 4th PacRim Breast and Prostate Cancer Meeting Canada -

Date Institution name Country Title
1984 Flinders University of South Australia Australia PhD
1976 University of Adelaide Australia B. Sc (Hons)

Date Title Institution Country
1987 - 1989 NHMRC CJ Martin Fellow University of Texas Southwestern Medical Center at Dallas United States

Year Citation
2026 Fang, D. M., Shrestha, R. K., German, B., Rahman, R., Townley, S. L., Xie, J., . . . Selth, L. A. (2026). USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.. Cell Death Dis, 17(1), 13 pages.
DOI Scopus1 WoS1
2026 Haggstrom, L., Middleton, K., Parker, A., Segara, D., Ong, A., Bingham, J., . . . Lim, E. (2026). The WinPro trial: window-of-opportunity study of endocrine therapy with micronised progesterone in ER-positive breast cancer. npj Breast Cancer, 1-24.
DOI
2025 Heydarlou, H., Hodson, L. J., Dorraki, M., Hickey, T. E., Tilley, W. D., Smith, E., . . . Farajpour, A. (2025). A Deep Learning Approach for the Classification of Fibroglandular Breast Density in Histology Images of Human Breast Tissue. Cancers, 17(3), 449-1-449-26.
DOI Scopus1 WoS1 Europe PMC2
2025 Lawrence, M. G., Keerthikumar, S., Townley, S. L., Clark, A. K., Cuffe, G. B., Laven-Law, G., . . . Selth, L. A. (2025). Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.. European urology focus, 11(5), S2405-4569(25)00073-2.
DOI Scopus5 WoS5 Europe PMC4
2024 Hosseinzadeh, L., Kikhtyak, Z., Laven-Law, G., Pederson, S. M., Puiu, C. G., D'Santos, C. S., . . . Hickey, T. E. (2024). The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. Genome Biol, 25(1), 44-1-44-28.
DOI Scopus17 WoS16 Europe PMC16
2024 Palmieri, C., Linden, H., Birrell, S. N., Wheelwright, S., Lim, E., Schwartzberg, L. S., . . . Overmoyer, B. (2024). Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. The Lancet Oncology, 25(3), 317-325.
DOI Scopus43 WoS42 Europe PMC41
2024 Bhuva, D. D., Tan, C. W., Salim, A., Marceaux, C., Pickering, M. A., Chen, J., . . . Davis, M. J. (2024). Library size confounds biology in spatial transcriptomics data. Genome Biology, 25(1), 99-1-99-10.
DOI Scopus27 WoS28 Europe PMC53
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Research, 84(14), 2313-2332.
DOI Scopus50 WoS51 Europe PMC45
2024 Liu, W., Mäkinen, V. -P., Tilley, W. D., & Pederson, S. M. (2024). sSNAPPY: an R/Bioconductor package for single-sample directional pathway perturbation analysis. F1000Research, 13, 628-653.
DOI
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(6), 1092-1105.
DOI Scopus12 WoS13 Europe PMC15
2024 De Ieso, M. L., Aldoghachi, A. F., Tilley, W. D., & Dwyer, A. R. (2024). Are androgen receptor agonists a treatment option in bladder cancer?. The Journal of Steroid Biochemistry and Molecular Biology, 245, 106623-1-106623-5.
DOI Scopus3 WoS3 Europe PMC2
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719.
DOI Scopus1 WoS2 Europe PMC2
2024 Srinivasan, S., Kryza, T., Bock, N., Tse, B. W. C., Sokolowski, K. A., Janaththani, P., . . . Berndt, S. I. (2024). A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nature Communications, 15(1), 9587-1-9587-21.
DOI Scopus11 WoS12 Europe PMC11
2023 Raths, F., Karimzadeh, M., Ing, N., Martinez, A., Yang, Y., Qu, Y., . . . Knott, S. R. V. (2023). The molecular consequences of androgen activity in the human breast. Cell Genomics, 3(3), 100272-1-100272-29.
DOI Scopus26 WoS24 Europe PMC31
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Horsfall, A. J., Chav, T., Pederick, J. L., Kikhtyak, Z., Vandborg, B. C., Kowalczyk, W., . . . Bruning, J. B. (2023). Designing Fluorescent Nuclear Permeable Peptidomimetics to Target Proliferating Cell Nuclear Antigen. Journal of Medicinal Chemistry, 66(15), 10354-10363.
DOI Scopus1 WoS1 Europe PMC1
2023 Prekovic, S., Chalkiadakis, T., Roest, M., Roden, D., Lutz, C., Schuurman, K., . . . Zwart, W. (2023). Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.. EMBO molecular medicine, 15(12), e17737.
DOI Scopus22 WoS22 Europe PMC26
2023 Wang, A., Shen, J., Rodriguez, A. A., Saunders, E. J., Chen, F., Janivara, R., . . . Weinstein, S. (2023). Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics, 55(12), 2065-2074.
DOI Scopus124 WoS123 Europe PMC134
2023 Mustafa, E. H., Laven-Law, G., Kikhtyak, Z., Nguyen, V., Ali, S., Pace, A. A., . . . Hickey, T. E. (2023). Selective inhibition of CDK9 in triple negative breast cancer. Oncogene, 43(3), 202-215.
DOI Scopus23 WoS23 Europe PMC17
2023 Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2023). Portable NMR for the investigation of models of mammographic density <i>ex vivo</i>: Androgens antagonise the promotional effect of oestrogen. BIOMEDICAL SPECTROSCOPY AND IMAGING, 10(3-4), 77-97.
DOI WoS1
2022 A, M., Owen, K. L., Townley, S., Zanker, D., Rollin, S. P. G., Hanson, A. R., . . . Selth, L. A. (2022). Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer research communications, 2(7), 706-724.
DOI Scopus18 WoS20 Europe PMC19
2021 Kenigsberg, A. P., Tilley, W. D., & Raj, G. V. (2021). Jean Wilson and His Legacy, 50 Years and Counting. Urology, 153, 1-5.
DOI
2021 Conti, D. V., Darst, B. F., Moss, L. C., Saunders, E. J., Sheng, X., Chou, A., . . . Haiman, C. A. (2021). Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 53(1), 65-75.
DOI Scopus377 WoS379 Europe PMC432
2021 Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17.
DOI Scopus47 WoS48 Europe PMC50
2021 Conti, D. V., Darst, B. F., Moss, L. C., Saunders, E. J., Sheng, X., Chou, A., . . . Haiman, C. A. (2021). Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.. Nature genetics, 53(3), 413.
DOI Scopus10 WoS7 Europe PMC7
2021 Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2021). The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nature Medicine, 27(2), 310-320.
DOI Scopus215 WoS205 Europe PMC205
2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993.
DOI Scopus70 WoS69 Europe PMC68
2021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
DOI Scopus80 WoS76 Europe PMC86
2021 Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2021). Corrigendum: Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo (Front. Cell Dev. Biol., (2020), 8, 599, 10.3389/fcell.2020.00599). Frontiers in Cell and Developmental Biology, 9, 678589.
DOI Scopus1 WoS1 Europe PMC1
2021 Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., . . . Simpson, K. J. (2021). High-throughput imaging assay for drug screening of 3D prostate cancer organoids. SLAS Discovery, 26(9), 1107-1124.
DOI Scopus66 WoS63 Europe PMC59
2021 Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021). Androgen receptor signaling in prostate cancer genomic subtypes. Cancers, 13(13), 3272.
DOI Scopus19 WoS17 Europe PMC16
2021 Hickey, T. E., Dwyer, A. R., & Tilley, W. D. (2021). Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. British Journal of Cancer, 125(12), 1599-1601.
DOI Scopus6 WoS6 Europe PMC7
2021 Horsfall, A. J., Vandborg, B., Kikhtyak, Z., Scanlon, D. B., Tilley, W. D., Hickey, T. E., . . . Abell, A. D. (2021). A cell permeable bimane-constrained PCNA-interacting peptide. RSC Chemical Biology, 2(5), 1499-1508.
DOI Scopus5 WoS5 Europe PMC3
2021 Davies, A., Nouruzi, S., Ganguli, D., Namekawa, T., Thaper, D., Linder, S., . . . Zoubeidi, A. (2021). An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.. Nature cell biology, 23(9), 33 pages.
DOI Scopus141 WoS136 Europe PMC159
2021 Che, M., Chaturvedi, A., Munro, S. A., Pitzen, S. P., Ling, A., Zhang, W., . . . Dehm, S. M. (2021). Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 12(1), 6377-1-6377-15.
DOI Scopus29 WoS30 Europe PMC38
2020 Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020). Targeting CDK2 in cancer: challenges and opportunities for therapy.. Drug discovery today, 25(2), 406-413.
DOI Scopus313 WoS296 Europe PMC260
2020 Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M. S., Butler, L. M., McNeil, C. M., O'Toole, S. A., . . . Ricciardelli, C. (2020). Elevated levels of tumor apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987.
DOI Scopus35 WoS32 Europe PMC34
2020 Flach, K. D., Periyasamy, M., Jadhav, A., Dorjsuren, D., Siefert, J. C., Hickey, T. E., . . . Zwart, W. (2020). Endonuclease FEN1 coregulates ERα activity and provides a novel drug interface in tamoxifen resistant breast cancer. Cancer Research, 80(10), 1914-1926.
DOI Scopus28 WoS27 Europe PMC25
2020 Portman, N., Milioli, H. H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K. J., . . . Lim, E. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.. Breast cancer research : BCR, 22(1), 87.
DOI Scopus64 WoS59 Europe PMC62
2020 Huang, X., Reye, G., Momot, K. I., Blick, T., Lloyd, T., Tilley, W. D., . . . Hugo, H. J. (2020). Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo.. Front Cell Dev Biol, 8, 599.
DOI Scopus21 WoS19 Europe PMC16
2020 Hollis, B., Day, F. R., Busch, A. S., Thompson, D. J., Soares, A. L. G., Timmers, P. R. H. J., . . . Butler, L. (2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nature Communications, 11(1), 1536-1-1536-10.
DOI Scopus55 Europe PMC59
2019 Tarulli, G., Laven-Law, G., Shehata, M., Walters, K., Denis, I., Rahman, M., . . . Hickey, T. (2019). Androgen receptor signalling promotes a luminal phenotype in mammary epithelial cells. Journal of Mammary Gland Biology and Neoplasia, 24(1), 99-108.
DOI Scopus13 WoS10 Europe PMC11
2019 Warren, A., Massie, C., Watt, K., Luko, K., Orafidiya, F., Selth, L., . . . Asim, M. (2019). A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 38(7), 1136-1150.
DOI Scopus20 WoS19 Europe PMC17
2019 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. G. (2019). An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 144(5), 1151-1159.
DOI Scopus14 WoS15 Europe PMC14
2019 Chia, K. M., Milioli, H., Portman, N., Laven-Law, G., Coulson, R., Yong, A., . . . Lim, E. (2019). Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine-Related Cancer, 26(2), 251-264.
DOI Scopus35 WoS34 Europe PMC36
2019 Schumacher, F. R., Olama, A. A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., . . . Rosenstein, B. S. (2019). Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8). Nature Genetics, 51(2), 363.
DOI Scopus12 WoS13 Europe PMC17
2019 Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019). Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. Journal of Medicinal Chemistry, 62(9), 4233-4251.
DOI Scopus255 WoS249 Europe PMC204
2019 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Ranu, H. (2019). Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1). Nature Communications, 10(1), 5 pages.
DOI Scopus1 WoS1 Europe PMC1
2019 Fernandes, R. C., Hickey, T. E., Tilley, W. D., & Selth, L. A. (2019). Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. Endocrine-Related Cancer, 26(5), R237-R257.
DOI Scopus23 WoS23 Europe PMC22
2019 Moore, N. L., Hanson, A. R., Ebrahimie, E., Hickey, T. E., & Tilley, W. D. (2019). ANTI-proliferative transcriptional effects of medroxyprogesterone acetate in Estrogen receptor positive breast cancer cells are predominantly mediated by ThE progesterone receptor.. Journal of Steroid Biochemistry and Molecular Biology, 199, 105548.
DOI Scopus16 WoS13 Europe PMC12
2018 Luo, J., Attard, G., Balk, S., Bevan, C., Burnstein, K., Cato, L., . . . Raj, G. (2018). Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 73(5), 715-723.
DOI Scopus116 WoS114 Europe PMC110
2018 Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., . . . Tilley, W. (2018). The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research, 24(10), 2328-2341.
DOI Scopus79 WoS75 Europe PMC76
2018 Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19.
DOI Scopus25 WoS21 Europe PMC22
2018 Pillman, K. A., Phillips, C. A., Roslan, S., Toubia, J., Dredge, B. K., Bert, A. G., . . . Gregory, P. A. (2018). miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. EMBO Journal, 37(13), 20 pages.
DOI Scopus99 WoS99 Europe PMC99
2018 Schumacher, F., Al Olama, A., Berndt, S., Benlloch, S., Ahmed, M., Saunders, E., . . . Lu, Y. (2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 50(7), 928-936.
DOI Scopus703 WoS690 Europe PMC767
2018 Dadaev, T., Saunders, E., Newcombe, P., Anokian, E., Leongamornlert, D., Brook, M., . . . Sellers, T. (2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 9(1), 19 pages.
DOI Scopus91 WoS87 Europe PMC99
2018 Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337.
DOI Scopus41 WoS45 Europe PMC46
2018 Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622.
DOI Scopus107 WoS105 Europe PMC109
2018 Lawrence, M., Obinata, D., Sandhu, S., Selth, L., Wong, S., Porter, L., . . . Frydenberg, M. (2018). Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European Urology, 74(5), 562-572.
DOI Scopus104 WoS101 Europe PMC96
2018 Snell, C., Gough, M., Liu, C., Middleton, K., Pyke, C., Shannon, C., . . . Tilley, W. (2018). Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b. British Journal of Cancer, 119(11), 1316-1325.
DOI Scopus11 WoS11 Europe PMC11
2018 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Butler, L. (2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 9(1), 4616-1-4616-11.
DOI Scopus50 WoS47 Europe PMC49
2017 Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34.
DOI Scopus99 WoS98 Europe PMC91
2017 Nelson, A., Groen, A., Miller, J., Warren, A., Holmes, K., Tarulli, G., . . . Carroll, J. (2017). Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Molecular and Cellular Endocrinology, 440(C), 138-150.
DOI Scopus106 WoS108 Europe PMC96
2017 Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M., & Tilley, W. D. (2017). Deciphering the divergent roles of progestogens in breast cancer. Nature Reviews Cancer, 17(1), 54-64.
DOI Scopus109 WoS103 Europe PMC91
2017 Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034.
DOI Scopus105 WoS105 Europe PMC101
2017 Nelson, A. W., Groen, A. J., Miller, J. L., Warren, A. Y., Holmes, K. A., Tarulli, G. A., . . . Carroll, J. S. (2017). Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138–150] (S0303720716304853)(10.1016/j.mce.2016.11.016). Molecular and Cellular Endocrinology, 443(C), 175.
DOI Scopus3 WoS2 Europe PMC1
2017 Miao, L., Yang, L., Li, R., Rodrigues, D., Crespo, M., Hsieh, J., . . . Raj, G. (2017). Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Research, 77(11), 3101-3112.
DOI Scopus79 WoS80 Europe PMC82
2017 Paltoglou, S., Das, R., Townley, S., Hickey, T., Tarulli, G., Coutinho, I., . . . Selth, L. (2017). Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Research, 77(13), 3417-3430.
DOI Scopus88 WoS83 Europe PMC98
2017 Ponnusamy, S., Coss, C., Thiyagarajan, T., Watts, K., Hwang, D. -J., He, Y., . . . Narayanan, R. (2017). Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Research, 77(22), 6282-6298.
DOI Scopus82 WoS82 Europe PMC77
2016 Asim, M., Massie, C., Orafidiya, F., Pértega-Gomes, N., Warren, A., Esmaeili, M., . . . Neal, D. (2016). Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target. Journal of the National Cancer Institute, 108(5), djv371-1-djv371-13.
DOI Scopus51 WoS49 Europe PMC50
2016 Castro, M., De Santiago, I., Campbell, T., Vaughn, C., Hickey, T., Ross, E., . . . Meyer, K. (2016). Regulators of genetic risk of breast cancer identified by integrative network analysis. Nature Genetics, 48(1), 12-21.
DOI Scopus172 WoS166 Europe PMC186
2016 Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13.
DOI Scopus12 WoS11 Europe PMC9
2016 Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page.
DOI Europe PMC1
2016 Philp, L., Day, T., Butler, M., Laven-Law, G., Jindal, S., Hickey, T., . . . Tilley, W. (2016). Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice. Scientific Reports, 6(1), 28950-1-28950-14.
DOI Scopus9 WoS9 Europe PMC10
2016 Singhal, H., Greene, M., Tarulli, G., Zarnke, A., Bourgo, R., Laine, M., . . . Greene, G. (2016). Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Science Advances, 2(6), e1501924.
DOI Scopus121 WoS120 Europe PMC128
2016 Hu, D., Selth, L., Tarulli, G., Meech, R., Wijayakumara, D., Chanawong, A., . . . Hickey, T. (2016). Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Research, 76(19), 5881-5893.
DOI Scopus55 WoS53 Europe PMC51
2016 Lim, E., Palmieri, C., & Tilley, W. D. (2016). Renewed interest in the progesterone receptor in breast cancer. British Journal of Cancer, 115(8), 909-911.
DOI Scopus35 WoS35 Europe PMC30
2016 Lim, E., Tarulli, G., Portman, N., Hickey, T., Tilley, W., & Palmieri, C. (2016). Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer, 23(12), T227-T241.
DOI Scopus37 WoS32 Europe PMC31
2016 Coutinho, I., Day, T., Tilley, W., & Selth, L. (2016). Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocrine-Related Cancer, 23(12), T179-T197.
DOI Scopus172 WoS162 Europe PMC164
2016 Tilley, W. D. (2016). Novel twists in hormone-mediated carcinogenesis. Endocrine-Related Cancer, 23(12), E9-E12.
DOI
2016 Bonilla, C., Lewis, S. J., Martin, R. M., Donovan, J. L., Hamdy, F. C., Neal, D. E., . . . Tilley, W. (2016). Pubertal development and prostate cancer risk: mendelian randomization study in a population-based cohort. BMC Medicine, 14(1), 66.
DOI Scopus45 WoS42 Europe PMC42
2015 Tuck, A., Mottershead, D., Fernandes, H., Norman, R., Tilley, W., Robker, R., & Hickey, T. (2015). Mouse GDF9 decreases KITL gene expression in human granulosa cells. Endocrine, 48(2), 686-695.
DOI Scopus7 WoS5 Europe PMC2
2015 Chan, S., Selth, L., Li, Y., Nyquist, M., Miao, L., Bradner, J., . . . Dehm, S. (2015). Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 43(12), 5880-5897.
DOI Scopus136 WoS135 Europe PMC142
2015 Tuck, A., Robker, R., Norman, R., Tilley, W., & Hickey, T. (2015). Expression and localisation of c-kit and KITL in the adult human ovary. Journal of Ovarian Research, 8(1), 31-1-31-12.
DOI Scopus31 WoS30 Europe PMC28
2015 Mohammed, H., Russell, I., Stark, R., Rueda, O., Hickey, T., Tarulli, G., . . . Carroll, J. (2015). Progesterone receptor modulates ERα action in breast cancer. Nature, 523(7560), 313-317.
DOI Scopus594 WoS550 Europe PMC549
2015 Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818.
DOI Scopus29 WoS29 Europe PMC30
2015 Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., . . . Carroll, J. S. (2015). Erratum: Progesterone receptor modulates ERα action in breast cancer (Nature (2015) 523 313-317 DOI:10.1038/nature14583). Nature, 526(7571), 144.
DOI Scopus12 WoS16 Europe PMC11
2015 Tarulli, G., Laven-Law, G., Shakya, R., Tilley, W., & Hickey, T. (2015). Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation. Journal of Mammary Gland Biology and Neoplasia, 20(1-2), 75-91.
DOI Scopus16 WoS16 Europe PMC15
2015 Hickey, T., Irvine, C., Dvinge, H., Tarulli, G., Hanson, A., Ryan, N., . . . Selth, L. (2015). Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget, 6(42), 44728-44744.
DOI Scopus91 WoS82 Europe PMC82
2015 Raj, G. V., Selth, L. A., Day, T. K., & Tilley, W. D. (2015). Evolution of androgen deprivation therapy. Cancer Forum, 39(3), 189-194.
WoS1
2015 Stegeman, S., Amankwah, E., Klein, K., O Mara, T. A., Kim, D., Lin, H. Y., . . . Luedeke, M. (2015). A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discovery, 5(4), 368-379.
DOI Scopus58 WoS59 Europe PMC52
2015 Al Olama, A. A., Benlloch, S., Antoniou, A. C., Giles, G., Severi, G., Neal, D. E., . . . Mason, M. (2015). Risk analysis of prostate cancer in practical, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiology Biomarkers and Prevention, 24(7), 1121-1129.
DOI Scopus55 WoS52 Europe PMC49
2014 Hu, D., Hickey, T., Irvine, C., Wijayakumara, D., Lu, L., Tilley, W., . . . MacKenzie, P. (2014). Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Hormones and Cancer, 5(2), 61-71.
DOI Scopus61 WoS56 Europe PMC57
2014 Robinson, J., Hickey, T., Warren, A., Vowler, S., Carroll, T., Lamb, D., . . . Carroll, J. (2014). Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene, 33(50), 5666-5674.
DOI Scopus77 WoS74 Europe PMC83
2014 Oh, T., Bailey, P., Dray, E., Smith, A., Goode, J., Eriksson, N., . . . Muscat, G. (2014). PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Molecular Endocrinology, 28(7), 1166-1185.
DOI Scopus54 WoS49 Europe PMC47
2014 Ochnik, A., Moore, N., Jankovic-Karasoulos, T., Bianco-Miotto, T., Ryan, N., Thomas, M., . . . Hickey, T. (2014). Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 21(1), 79-88.
DOI Scopus19 WoS16 Europe PMC17
2014 Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21.
DOI Scopus39 WoS35 Europe PMC36
2014 Das, R., Gregory, P., Hollier, B., Tilley, W., & Selth, L. (2014). Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends in Molecular Medicine, 20(11), 643-651.
DOI Scopus22 WoS22 Europe PMC21
2014 Hilton, H., Doan, T., Dinny Graham, J., Oakes, S., Silvestri, A., Santucci, N., . . . Clarke, C. (2014). Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget, 5(18), 8651-8664.
DOI Scopus29 WoS26 Europe PMC26
2014 Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 21(4), T183-T202.
DOI Scopus28 WoS25 Europe PMC22
2014 McNamara, K. M., Moore, N. L., Hickey, T. E., Sasano, H., & Tilley, W. D. (2014). Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer, 21(4), T161-T181.
DOI Scopus121 WoS112 Europe PMC101
2014 Doan, T., Eriksson, N., Graham, D., Funder, J., Simpson, E., Kuczek, E., . . . Clarke, C. (2014). Breast cancer prognosis predicted by nuclear receptor-coregulator networks. Molecular Oncology, 8(5), 998-1013.
DOI Scopus19 WoS18 Europe PMC16
2014 Akram, O. N., DeGraff, D. J., Sheehan, J. H., Tilley, W. D., Matusik, R. J., Ahn, J. M., & Raj, G. V. (2014). Tailoring peptidomimetics for targeting protein-protein interactions. Molecular Cancer Research, 12(7), 967-978.
DOI Scopus45 WoS42 Europe PMC36
2014 Nelson, A. W., Tilley, W. D., Neal, D. E., & Carroll, J. S. (2014). Estrogen receptor beta in prostate cancer: friend or foe?. Endocrine-Related Cancer, 21(4), T219-T234.
DOI Scopus97 WoS84 Europe PMC74
2014 Claessens, F., & Tilley, W. (2014). Androgen signalling and steroid receptor crosstalk in endocrine cancers. Endocrine Related Cancer, 21(4), E3-E5.
DOI Scopus6 WoS6 Europe PMC6
2013 Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491.
DOI Scopus102 WoS91 Europe PMC90
2013 Knower, K., Chand, A., Eriksson, N., Takagi, K., Miki, Y., Sasano, H., . . . Clyne, C. (2013). Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 142(1), 211-223.
DOI Scopus43 WoS41 Europe PMC36
2013 Philp, L., Butler, M., Hickey, T., Butler, L., Tilley, W., & Day, T. (2013). SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer, 4(6), 343-357.
DOI Scopus30 WoS30 Europe PMC33
2013 Lawrence, M., Ormsby, R., Blyth, B., Bezak, E., England, G., Newman, M., . . . Sykes, P. (2013). Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model. Radiation Research, 180(4), 376-388.
DOI Scopus5 WoS5 Europe PMC5
2013 Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823.
DOI Scopus21 WoS19 Europe PMC20
2013 Lawrence, M., Blyth, B., Ormsby, R., Tilley, W., & Sykes, P. (2013). False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models. Transgenic Research, 22(5), 1037-1047.
DOI Scopus12 WoS8 Europe PMC8
2013 Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487.
DOI Scopus119 WoS116 Europe PMC112
2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650.
DOI Scopus118 WoS115 Europe PMC108
2013 Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704.
DOI Scopus52 WoS51 Europe PMC47
2013 Abankwa, D., Millard, S., Martel, N., Choong, C., Yang, M., Butler, L., . . . Leong, G. (2013). Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 14(10), 1-9.
DOI Scopus15 WoS14 Europe PMC14
2013 Butler, M., Yang, X., Ricciardelli, C., Liang, X., Norman, R., Tilley, W., & Hickey, T. (2013). Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 99(7), 2076-2083.
DOI Scopus5 WoS5 Europe PMC6
2013 Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11.
DOI Scopus130 WoS128 Europe PMC124
2013 Butler, M., Ricciardelli, C., Tilley, W., & Hickey, T. (2013). Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Hormones and Cancer, 4(3), 154-164.
DOI Scopus23 WoS20 Europe PMC22
2013 Muscat, G., Eriksson, N., Byth, K., Loi, S., Graham, D., Jindal, S., . . . Clarke, C. (2013). Research resource: Nuclear receptors as transcriptome: Discriminant and prognostic value in breast cancer. Molecular Endocrinology, 27(2), 350-365.
DOI Scopus93 WoS96 Europe PMC93
2013 Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218.
DOI Scopus47 WoS43 Europe PMC37
2013 Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193.
DOI Scopus16 WoS14 Europe PMC14
2013 Lange, C. A., Hankinson, S. E., & Tilley, W. D. (2013). Updates from the Editors. Hormones and Cancer, 4(3), 121-122.
DOI
2012 Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149.
DOI Scopus397 WoS389 Europe PMC383
2012 Need, E., Selth, L., Harris, T., Birrell, S., Tilley, W., & Buchanan, G. (2012). Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Molecular Endocrinology, 26(11), 1941-1952.
DOI Scopus78 WoS73 Europe PMC74
2012 Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68.
DOI Scopus19 WoS17 Europe PMC19
2012 Hickey, T., Robinson, J., Carroll, J., & Tilley, W. (2012). Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Molecular Endocrinology, 26(8), 1252-1267.
DOI Scopus256 WoS233 Europe PMC224
2012 Dowhan, D., Harrison, M., Eriksson, N., Bailey, P., Pearen, M., Fuller, P., . . . Muscat, G. (2012). Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrine-Related Cancer, 19(4), 509-526.
DOI Scopus38 WoS38 Europe PMC36
2012 Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613.
DOI Scopus48 WoS48 Europe PMC45
2012 Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113.
DOI Scopus39 WoS34 Europe PMC33
2012 Dean, J., McClendon, A., Hickey, T., Butler, L., Tilley, W., Witkiewicz, A., & Knudsen, E. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 11(14), 2756-2761.
DOI Scopus206 WoS191 Europe PMC189
2012 Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570.
DOI Scopus98 WoS97 Europe PMC96
2012 Moore, N., Hickey, T., Butler, L., & Tilley, W. (2012). Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 357(1-2), 60-70.
DOI Scopus42 WoS42 Europe PMC33
2012 Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672.
DOI Scopus35 WoS33 Europe PMC34
2012 Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661.
DOI Scopus166 WoS152 Europe PMC140
2012 Robinson, J. L., Brown, G. D., Neal, D. E., Tilley, W. D., & Carroll, J. S. (2012). Androgen receptor driven transcription in a subtype of estrogen receptor negative breast cancer is controlled by FoxA1. Cancer Research, 72(Suppl.8), 1 page.
DOI
2012 Robinson, J. L. L., MacArthur, S., Ross-Innes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., & Carroll, J. S. (2012). Erratum: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 (The EMBO Journal (2012) 31 (1617) DOI:10.1038/emboj.2012.59). EMBO Journal, 31(6), 1617.
DOI Scopus2 WoS3
2011 Robinson, J., MacArthur, S., Ross-Innes, C., Tilley, W., Neal, D., Mills, I., & Carroll, J. (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 30(15), 3019-3027.
DOI Scopus257 WoS241 Europe PMC238
2011 Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11.
DOI Scopus49 WoS39 Europe PMC36
2011 Peters, A., Ingman, W., Tilley, W., & Butler, L. (2011). Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology, 152(10), 3728-3737.
DOI Scopus59 WoS51 Europe PMC51
2011 Buchanan, G., Need, E., Barrett, J., Bianco-Miotto, T., Thompson, V., Butler, L., . . . Coetzee, G. (2011). Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 342(1-2), 20-31.
DOI Scopus13 WoS14 Europe PMC14
2011 Atlantis, E., Lange, K., Goldney, R., Martin, S., Haren, M., Taylor, A., . . . Wittert, G. (2011). Specific medical conditions associated with clinically significant depressive symptoms in men. Social Psychiatry and Psychiatric Epidemiology, 46(12), 1303-1312.
DOI Scopus30 WoS23 Europe PMC22
2010 Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., . . . Ricciardelli, C. (2010). Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention, 19(10), 2611-2622.
DOI Scopus144 WoS122 Europe PMC113
2010 Hu, D., Gardner-Stephen, D., Severi, G., Gregory, P., Treloar, J., Giles, G., . . . MacKenzie, P. (2010). A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide. Molecular Pharmacology, 78(4), 714-722.
DOI Scopus30 WoS27 Europe PMC27
2010 Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Dodd, T., Cohen, P., Marshall, V., . . . Horsfall, D. (2010). Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiology Biomarkers & Prevention, 19(7), 1755-1765.
DOI Scopus12 WoS12 Europe PMC11
2010 Callen, D., Ricciardelli, C., Butler, M., Stapleton, A., Stahl, J., Kench, J., . . . Holm, R. (2010). Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 23(4), 1045-1052.
DOI Scopus14 WoS13 Europe PMC13
2010 Baglietto, L., Severi, G., English, D., Krishnan, K., Hopper, J., McLean, C., . . . Giles, G. (2010). Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiology Biomarkers & Prevention, 19(2), 492-502.
DOI Scopus98 WoS91 Europe PMC82
2010 Risbridger, G., Davis, I., Birrell, S., & Tilley, W. (2010). Breast and prostate cancer: more similar than different. Nature Reviews. Cancer, 10(3), 205-212.
DOI Scopus213 WoS207 Europe PMC189
2010 Need, E. F., O Loughlin, P. D., Armstrong, D. T., Haren, M. T., Martin, S. A., Tilley, W. D., . . . Buchanan, G. (2010). Serum testosterone bioassay evaluation in a large male cohort. Clinical endocrinology, 72(1), 87-98.
DOI Scopus5 WoS4 Europe PMC4
2010 Ochnik, A. M., Jankovic-Karasoulos, T., Cops, E. J., Birrell, S. N., Butler, L. M., Jindall, S., . . . Hickey, T. E. (2010). Medroxyprogesterone acetate impedes 5 alpha-dihydrotesterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. Cancer Research, 70(Suppl 8), 4 pages.
DOI
2010 Murti, K., Butler, L. M., Sakko, A., Ricciardelli, C., Mitto, T. B., Octnick, A., . . . Tilley, W. D. (2010). Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 19(1), 5-13.
DOI Scopus2 WoS2
2009 Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630.
DOI Scopus5 Europe PMC4
2009 Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140.
DOI Scopus356 WoS332 Europe PMC293
2009 Gardiner, R., Sweeney, C., & Tilley, W. (2009). Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach. European Urology, 56(2), 245-246.
DOI Scopus8 WoS7 Europe PMC6
2009 Need, E., Scher, H., Peters, A., Moore, N., Cheong, A., Ryan, C., . . . Buchanan, G. (2009). A Novel Androgen Receptor Amino Terminal Region Reveals Two Classes of Amino/Carboxyl Interaction-Deficient Variants with Divergent Capacity to Activate Responsive Sites in Chromatin. Endocrinology, 150(6), 2674-2682.
DOI Scopus25 WoS24 Europe PMC25
2009 Ricciardelli, C., Sakko, A., Stahl, J., Tilley, W., Marshall, V., & Horsfall, D. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate, 69(7), 761-769.
DOI Scopus18 WoS17 Europe PMC14
2009 Chiam, K., Tilley, W., Butler, L., & Bianco-Miotto, T. (2009). The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica et Biophysica Acta-Reviews on Cancer, 1795(2), 104-109.
DOI Scopus16 WoS17 Europe PMC15
2009 Baglietto, L., English, D., Hopper, J., MacInnis, R., Morris, H., Tilley, W., . . . Giles, G. (2009). Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Research and Treatment, 115(1), 171-179.
DOI Scopus113 WoS106 Europe PMC108
2008 Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382.
DOI Scopus125 WoS113 Europe PMC102
2008 Sakko, A., Butler, M., Byers, S., Reinboth, B., Stahl, C., Kench, J., . . . Ricciardelli, C. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiology Biomarkers & Prevention, 17(9), 2488-2497.
DOI Scopus26 WoS26 Europe PMC21
2008 Cops, E., Bianco-Miotto, T., Moore, N., Clarke, C., Birrell, S., Butler, L., & Tilley, W. (2008). Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 110(3-5), 236-243.
DOI Scopus67 WoS64 Europe PMC58
2008 Ricciardelli, C., Jackson, M., Choong, C., Stahl, J., Marshall, V., Horsfall, D., & Tilley, W. (2008). Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate, 68(8), 830-838.
DOI Scopus40 WoS38 Europe PMC38
2007 Reichardt, J., & Tilley, W. (2007). The 3rd Pacific Rim meeting on breast and prostate cancer: Progress in hormonal carcinogenesis and the enduring influence of Ron Ross. Cancer Research, 67(10), 4550-4552.
DOI Scopus1 Europe PMC1
2007 Buchanan, G., Ricciardelli, C., Harris, J., Prescott, J., Yu, Z., Jia, L., . . . Tilley, W. (2007). Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Research, 67(20), 10087-10096.
DOI Scopus79 WoS76 Europe PMC73
2007 Jariwala, U., Prescott, J., Jia, L., Barski, A., Pregizer, S., Cogan, J., . . . Frenkel, B. (2007). Identification of novel androgen receptor target genes in prostate cancer. Molecular Cancer, 6(1), WWW 1-WWW 15.
DOI Scopus92 WoS84 Europe PMC76
2007 Birrell, S., Butler, L., Harris, J., Buchanan, G., & Tilley, W. (2007). Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 21(10), 2285-2293.
DOI Scopus83 WoS72 Europe PMC66
2007 Robzyk, K., Oen, H., Buchanan, G., Butler, L., Tilley, W., Mandal, A., . . . Caplan, A. (2007). Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 268(1-2), 67-74.
DOI Scopus9 WoS11 Europe PMC10
2007 Dwivedi, P., Anderson, P., Tilley, W., May, B., & Morris, H. (2007). Role of oncoprotein Growth Factor Independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): A comparative analysis in human prostate cancer and kidney cells. Journal of Steroid Biochemistry and Molecular Biology, 103(3-5 Sp Iss), 742-746.
DOI Scopus8 WoS6 Europe PMC6
2007 Ricciardelli, C., Russell, D., Ween, M., Mayne, K., Suwiwat, S., Byers, S., . . . Horsfall, D. (2007). Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. Journal of Biological Chemistry, 282(14), 10814-10825.
DOI Scopus140 WoS137 Europe PMC121
2007 Baglietto, L., English, D., Hopper, J., Morris, H., Tilley, W., & Giles, G. (2007). Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiology Biomarkers & Prevention, 16(4), 763-768.
DOI Scopus92 WoS71 Europe PMC68
2007 Sakko, A., Ricciardelli, C., Mayne, K., Dours-Zimmermann, M., Zimmermann, D., Neufing, P., . . . Horsfall, D. (2007). Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate, 67(3), 288-300.
DOI Scopus9 WoS9 Europe PMC7
2007 Marrocco, D., Tilley, W., Bianco-Miotto, T., Evdokiou, A., Scher, H., Rifkind, R., . . . Butler, L. (2007). Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 6(1), 51-60.
DOI Scopus97 WoS87 Europe PMC81
2007 Chmelar, R., Buchanan, G., Need, E., Tilley, W., & Greenberg, N. (2007). Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer, 120(4), 719-733.
DOI Scopus223 WoS200 Europe PMC183
2007 Hayes, V., Severi, G., Padilla, E., Morris, H., Tilley, W., Southey, M., . . . Giles, G. (2007). 5 α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. International Journal of Cancer, 120(4), 776-780.
DOI Scopus57 WoS50 Europe PMC42
2006 Zeng, G., Day, T., Hooker, A., Blyth, B., Bhat, M., Tilley, W., & Sykes, P. (2006). Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 602(1-2), 65-73.
DOI Scopus43 WoS38 Europe PMC34
2006 Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954.
DOI Scopus71 WoS64 Europe PMC54
2006 Severi, G., Hayes, V., Neufing, P., Padilla, E., Tilley, W., Eggleton, S., . . . Giles, G. (2006). Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiology Biomarkers & Prevention, 15(6), 1142-1147.
DOI Scopus27 WoS25 Europe PMC21
2006 Severi, G., Morris, H., MacInnis, R., English, D., Tilley, W., Hopper, J., . . . Giles, G. (2006). Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention, 15(6), 1137-1141.
DOI Scopus57 WoS56 Europe PMC44
2006 Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024.
DOI Scopus16 WoS15 Europe PMC16
2006 Severi, G., Morris, H., MacInnes, R., English, D., Tilley, W., Hopper, J., . . . Giles, G. (2006). Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiology Biomarkers & Prevention, 15(1), 86-91.
DOI Scopus164 WoS152 Europe PMC133
2005 Makridakis, N., Buchanan, G., Tilley, W., & Reichardt, J. (2005). Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in Bioscience, 10(SUPPL. 3), 2892-2903.
DOI Scopus6 WoS5 Europe PMC4
2005 Shen, H., Buchanan, G., Butler, L., Prescott, J., Henderson, M., Tilley, W., & Coetzee, G. (2005). GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.. Journal of Biological Chemistry, 386(1), 69-74.
DOI Scopus25 WoS25 Europe PMC22
2005 Buchanan, G., Birrell, S., Peters, A., Bianco-Miotto, T., Ramsay, K., Cops, E., . . . Tilley, W. (2005). Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research, 65(18), 8487-8496.
DOI Scopus64 WoS61 Europe PMC56
2005 Han, G., Buchanan, G., Ittmann, M., Harris, J., Yu, X., DeMayo, F., . . . Greenberg, N. (2005). Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America, 102(4), 1151-1156.
DOI Scopus163 WoS152 Europe PMC137
2004 Ricciardelli, C., Choong, C., Buchanan, G., Vivekanandan, S., Neufing, P., Stahl, J., . . . Tilley, W. (2004). Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate, 63(1), 19-28.
DOI Scopus104 WoS96 Europe PMC88
2004 Jia, L., Choong, C., Ricciardelli, C., Kim, J., Tilley, W., & Coetzee, G. (2004). Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Research, 64(7), 2619-2626.
DOI Scopus78 WoS69 Europe PMC64
2004 Buchanan, G., Yang, M., Cheong, A., Harris, J., Irvine, R., Lambert, P., . . . Tilley, W. (2004). Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics, 13(16), 1677-1692.
DOI Scopus182 WoS172 Europe PMC147
2004 Scher, H., Buchanan, G., Gerald, W., Butler, L., & Tilley, W. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 11(3), 459-476.
DOI Scopus213 WoS204 Europe PMC185
2004 Buchanan, G., Craft, C., Yang, M., Cheong, A., Prescott, J., Jia, L., . . . Tilley, W. (2004). PC-3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer. Prostate, 60(4), 352-366.
DOI Scopus32 WoS32 Europe PMC33
2004 Hooker, A., Morley, A., Tilley, W., & Sykes, P. (2004). Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 550(1-2), 1-10.
DOI Scopus11 WoS9 Europe PMC10
2004 Hollington, P., Neufing, P., Kallionis, B., Waring, P., Bentel, J., Wattchow, D., & Tilley, W. (2004). Expression and localization of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues. Anticancer Research, 24(2B), 955-962.
Scopus25 WoS25 Europe PMC21
2004 Suwiwat, S., Ricciardelli, C., Tammi, R., Tammi, M., Auvinen, P., Kosma, V., . . . Horsfall, D. (2004). Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clinical Cancer Research, 10(7), 2491-2498.
DOI Scopus137 WoS133 Europe PMC114
2004 Hall, R., Horsfall, D., Stahl, J., Vivekanandan, S., Ricciardelli, C., Stapleton, A., . . . Tilley, W. (2004). Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. Prostate, 58(2), 103-108.
DOI Scopus31 WoS33 Europe PMC33
2003 Zhang, L., Brereton, H., Hahn, M., Froscio, M., Tilley, W., Brown, M., & Barritt, G. (2003). Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Therapy, 10(8), 611-625.
DOI Scopus9 WoS7 Europe PMC8
2003 Severi, G., Giles, G., Southey, M., Tesoriero, A., Tilley, W., Neufing, P., . . . Hopper, J. (2003). ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. Journal of the National Cancer Institute, 95(11), 818-824.
DOI Scopus51 WoS46 Europe PMC43
2003 Kim, J., Jia, L., Tilley, W., & Coetzee, G. (2003). Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Research, 31(23), 6741-6747.
DOI Scopus36 WoS36 Europe PMC28
2003 Neufing, P., Kalionis, B., Horsfall, D., Ricciardelli, C., Stahl, J., Vivekanandan, S., . . . Tilley, W. (2003). Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues. Anticancer Research, 23(2B), 1479-1488.
Scopus20 WoS20 Europe PMC17
2003 Sakko, A., Ricciardelli, C., Mayne, K., Suwiwat, S., LeBaron, R., Marshall, V., . . . Horsfall, D. (2003). Modulation of prostate cancer cell attachment to matrix by Versican. Cancer Research, 63(16), 4786-4791.
Scopus80 WoS76 Europe PMC69
2003 Jia, L., Kim, J., Shen, H., Clark, P., Tilley, W., & Coetzee, G. (2003). Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Molecular Cancer Research, 1(5), 385-392.
Scopus62 WoS61 Europe PMC45
2002 James, A., Agoulnik, I., Harris, J., Buchanan, G., Tilley, W., Marcelli, M., . . . Weigel, N. (2002). A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Molecular Endocrinology, 16(12), 2692-2705.
DOI Scopus19 WoS16 Europe PMC15
2002 Buchanan, G., Irvine, R., Coetzee, G., & Tilley, W. (2002). Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer and Metastasis Reviews, 20(3-4), 207-223.
DOI Scopus147 WoS136 Europe PMC115
2002 Jackson, M., Roberts, J., Heckford, S., Ricciardelli, C., Stahl, J., Horsfall, D., & Tilley, W. (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Research, 62(3), 854-859.
Scopus173 WoS160 Europe PMC118
2001 Han, G., Foster, B., Mistry, S., Buchanan, G., Harris, J., Tilley, W., & Greenberg, N. (2001). Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Journal of Biological Chemistry, 276(14), 11204-11213.
DOI Scopus108 WoS107 Europe PMC89
2001 Buchanan, G., Yang, M., Harris, J., Nahm, H., Han, G., Moore, N., . . . Tilley, W. (2001). Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology, 15(1), 45-56.
DOI Scopus106 WoS98 Europe PMC77
2001 Sakko, A., Ricciardelli, C., Mayne, K., Tilley, W., LeBaron, R., & Horsfall, D. (2001). Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Research, 61(3), 926-930.
Scopus94 WoS89 Europe PMC77
2001 Buchanan, G., Greenberg, N., Scher, H., Harris, J., Marshall, V., & Tilley, W. (2001). Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research, 7(5), 1273-1281.
Scopus175 WoS156 Europe PMC113
2001 Tilley, W. D., Clarke, C. L., Birrell, S. N., & Bruchovsky, N. (2001). Hormones and cancer: new insights, new challenges. Trends in endocrinology and metabolism: TEM, 12(5), 186-188.
DOI Scopus4 Europe PMC3
2000 Park, J., Irvine, R., Buchanan, G., Koh, S., Park, J., Tilley, W., . . . Coetzee, G. (2000). Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Research, 60(21), 5946-5949.
Scopus159 WoS141 Europe PMC115
1999 Ricciardelli, C., Quinn, D., Raymond, W., McCaul, K., Sutherland, P., Stricker, P., . . . Horsfall, D. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Research, 59(10), 2324-2328.
Scopus53 WoS52 Europe PMC39
1999 Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D. (1999). Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Molecular and Cellular Endocrinology, 154(1-2), 11-20.
DOI Scopus106 WoS101 Europe PMC85
1999 Bentel, J. M., Pickering, M. A., Pollard, M., Clements, J. A., & Tilley, W. D. (1999). Androgen receptor expression in primary prostate cancers of Lobund- Wistar rats and in tumor-derived cell lines. In Vitro Cellular and Developmental Biology Animal, 35(10), 655-662.
DOI Scopus7 WoS6 Europe PMC4
1999 Clements, J. A., Rohde, P., Allen, V., Hyland, V. J., Samaratunga, M. L. T. H., Tilley, W. D., . . . Gardiner, R. A. (1999). Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. Journal of Urology, 161(4), 1337-1343.
DOI Scopus28 WoS25 Europe PMC14
1998 Zhang, S. X. D., Bentel, J. M., Ricciardelli, C., Horsfall, D. J., Haagensen, D. E., Marshall, V. R., & Tilley, W. D. (1998). Immunolocalization of apolipoprotein d, androgen receptor and prostate specific antigen in early stage prostate cancers. Journal of Urology, 159(2), 548-554.
DOI Scopus23 WoS22 Europe PMC19
1998 Hall, R. E., Clements, J. A., Birrell, S. N., & Tilley, W. D. (1998). Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. British Journal of Cancer, 78(3), 360-365.
DOI Scopus52 WoS47 Europe PMC38
1998 Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the Androgen Receptor in Human Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 3(1), 95-103.
DOI Scopus115 WoS107 Europe PMC94
1997 Ricciardelli, C., Mayne, K., Sykes, P. J., Raymond, W. A., McCaul, K., Marshall, V. R., . . . Horsfall, D. J. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clinical Cancer Research, 3(6), 983-992.
Scopus86 WoS83 Europe PMC63
1997 Jackson, M. W., Bentel, J. M., & Tilley, W. D. (1997). Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. Journal of Urology, 157(6), 2323-2328.
DOI Scopus180 WoS147 Europe PMC125
1996 Tilley, W. D., Buchanan, G., Hickey, T. E., & Bentel, J. M. (1996). Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research, 2(2), 277-285.
Scopus351 WoS324 Europe PMC231
1996 Hall, R. E., Aspinall, J. O., Horsfall, D. J., Birrell, S. N., Bentel, J. M., Sutherland, R. L., & Tilley, W. D. (1996). Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. British Journal of Cancer, 74(8), 1175-1180.
DOI Scopus70 WoS70 Europe PMC55
1996 Bentel, J. M., & Tilley, W. D. (1996). Androgen receptors in prostate cancer. Journal of Endocrinology, 151(1), 1-11.
DOI Scopus89 WoS84 Europe PMC53
1996 Choong, C. S., Sturm, M. J., Strophair, J. A., Mcculloch, R. K., Tilley, W. D., Leedman, P. J., & Hurley, D. M. (1996). Partial Androgen Insensitivity Caused by an Androgen Receptor Mutation at Amino Acid 907 (Gly→Arg) That Results in Decreased Ligand Binding Affinity and Reduced Androgen Receptor Messenger Ribonucleic Acid Levels. Journal of Clinical Endocrinology and Metabolism, 81(1), 236-243.
DOI Scopus17 WoS15 Europe PMC8
1995 van Wezel, I. L., Umapathysivam, K., Tilley, W. D., & Rodgers, R. J. (1995). Immunohistochemical localization of basic fibroblast growth factor in bovine ovarian follicles. Molecular and Cellular Endocrinology, 115(2), 133-140.
DOI Scopus76 WoS82 Europe PMC57
1995 Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995). Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. Journal of Clinical Oncology, 13(7), 1572-1577.
DOI Scopus82 WoS77 Europe PMC65
1995 Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., & Tilley, W. D. (1995). Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 52(5), 459-467.
DOI Scopus235 WoS238 Europe PMC196
1995 Greenberg, N. M., Demayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., . . . Rosen, J. M. (1995). Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America, 92(8), 3439-3443.
DOI Scopus1141 WoS1088 Europe PMC947
1995 Aspinall, J. O., Bentel, J. M., Horsfall, D. J., Haagensen, D. E., Marshall, V. R., & Tilley, W. D. (1995). Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues. Journal of Urology, 154(2), 622-628.
DOI Scopus37 WoS35 Europe PMC12
1995 Tilley, W. D., Bentel, J. M., Aspinall, J. O., Hall, R. E., & Horsfall, D. J. (1995). Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids, 60(1), 180-186.
DOI Scopus45 WoS44 Europe PMC41
1994 Ricciardelli, C., Horsfall, D. J., Sykes, P. J., Marshall, V. R., & Tilley, W. D. (1994). Effects of oestradiol 17-β and 5α-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression. Journal of Endocrinology, 140(3), 373-383.
DOI Scopus21 WoS19 Europe PMC13
1994 Horsfall, D. J., Mayne, K., Ricciardelli, C., Mohan, R., Skinner, J. M., Henderson, D. W., . . . Tilley, W. D. (1994). Age-related changes in guinea pig prostatic stroma. Laboratory Investigation, 70(5), 753-763.
DOI Scopus54 WoS47 Europe PMC38
1994 Hall, R. E., Birrell, S. N., Tilley, W. D., & Sutherland, R. L. (1994). MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European Journal of Cancer, 30A(4), 484-490.
DOI Scopus95 WoS93 Europe PMC83
1994 Tilley, W., Lim-Tio, S., Horsfall, D., Aspinall, J., Marshall, V., & Skinner, J. (1994). Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Research, 54(15), 4096-4102.
Scopus121 WoS120 Europe PMC90
1994 Horsfall, D. J., Mayne, K., Skinner, J. M., Saccone, G. T. P., Marshall, V. R., & Tilley, W. D. (1994). Glycosaminoglycans of guinea pig prostate fibromuscular stroma: influence of estrogen and androgen on levels and location of chondroitin sulfate. The Prostate, 25(6), 320-332.
DOI Scopus15 WoS16 Europe PMC11
1992 Hall, R. E., Tilley, W. D., McPhaul, M. J., & Sutherland, R. L. (1992). Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast‐cancer cells. International Journal of Cancer, 52(5), 778-784.
DOI Scopus43 WoS47 Europe PMC30
1992 Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1992). Molecular basis of androgen resistance. Journal of Endocrinological Investigation Official Journal of the Italian Scociety of Endocrinology, 15(2), 149-159.
DOI Scopus13 WoS17 Europe PMC8
1991 Gill, P. G., Tilley, W. D., De Young, N. J., Lensink, I. L., Dixon, P. D., & Horsfall, D. J. (1991). Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF. Breast Cancer Research and Treatment, 20(1), 53-62.
DOI Scopus14 WoS15 Europe PMC13
1991 McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., Isidro-Gutierrez, R. F., & Wilson, J. D. (1991). Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. Journal of Clinical Investigation, 87(4), 1413-1421.
DOI Scopus121 WoS125 Europe PMC78
1991 Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1991). Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg→Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function. Journal of Clinical Endocrinology and Metabolism, 73(2), 318-325.
DOI Scopus68 WoS71 Europe PMC33
1991 McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., & Wilson, J. D. (1991). Androgen resistance caused by mutations in the androgen receptor gene. FASEB Journal, 5(14), 2910-2915.
DOI Scopus87 WoS81 Europe PMC47
1990 Marcelli, M., Tilley, W. D., Wilson, C. M., Wilson, J. D., Griffin, J. E., & McPhaul, M. J. (1990). A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. Journal of Clinical Investigation, 85(5), 1522-1528.
DOI Scopus80 WoS89 Europe PMC47
1990 Marcelli, M., Tilley, W. D., Wilson, C. M., Griffin, J. E., Wilson, J. D., & McPhaul, M. J. (1990). Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: Premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. Molecular Endocrinology, 4(8), 1105-1116.
DOI Scopus149 WoS151 Europe PMC80
1990 Wilson, C. M., Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines. Cancer Research, 50(17), 5382-5386.
Scopus230 WoS233 Europe PMC141
1990 Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. Journal of Biological Chemistry, 265(23), 13776-13781.
DOI Scopus109 WoS112 Europe PMC76
1990 Husmann, D. A., Wilson, C. M., Mcphaul, M. J., Tilley, W. D., & Wilson, J. D. (1990). Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate. Endocrinology, 126(5), 2359-2368.
DOI Scopus153 WoS164 Europe PMC96
1990 Tilley, W. D., Marcelli, M., & McPhaul, M. J. (1990). Recent studies of the androgen receptor: new insights into old questions. Molecular and Cellular Endocrinology, 68(2-3), C7-C10.
DOI Scopus24 WoS24 Europe PMC13
1989 Horsfall, D. J., Goldsmith, K. G., Ricciardelli, C., Skinner, J. M., Tilley, W. D., & Marshall, V. R. (1989). Steroid hormone and epidermal growth factor receptors in meningiomas. Australian and New Zealand Journal of Surgery, 59(11), 881-888.
DOI Scopus17 WoS17 Europe PMC15
1989 Ricciardelli, C., Horsfall, D. J., Skinner, J. M., Henderson, D. W., Marshall, V. R., & Tilley, W. D. (1989). Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cellular &amp; Developmental Biology, 25(11), 1016-1024.
DOI Scopus29 WoS32 Europe PMC26
1989 Horsfall, D. J., Jarvis, L. R., Grimbaldeston, M. A., Tilley, W. D., & Orell, S. R. (1989). Immunocytochemical assay for oestrogen receptor in fine needle aspirates of breast cancer by video image analysis. British Journal of Cancer, 59(1), 129-134.
DOI Scopus17 WoS19 Europe PMC15
1989 Cooper, J. A., Rohan, T. E., Cant, E. L. M. K., Horsfall, D. J., & Tilley, W. D. (1989). Risk factors for breast cancer by oestrogen receptor status: A population-based case-control study. British Journal of Cancer, 59(1), 119-125.
DOI Scopus117 WoS105 Europe PMC81
1989 Tilley, W. D., Horsfall, D. J., Skinner, J. M., Henderson, D. W., & Marshall, V. R. (1989). Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. Prostate, 15(2), 195-210.
DOI Scopus19 WoS22 Europe PMC15
1989 Tilley, W. D., Marcelli, M., Wilson, J. D., & McPhaul, M. J. (1989). Characterization and expression of a cDNA encoding the human androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 86(1), 327-331.
DOI Scopus434 WoS446 Europe PMC246
1987 Tilley, W. D., Horsfall, D. J., McGee, M. A., Alderman, J. E., & Marshall, V. R. (1987). Effects of ageing and hormonal manipulations on the level of oestrogen receptors in the guinea-pig prostate. Journal of Endocrinology, 112(1), 139-144.
DOI Scopus12 WoS12 Europe PMC8
1987 van Haaften‐Day, C., Raghavan, D., Russell, P., Wills, E. J., Gregory, P., Tilley, W., & Horsfall, D. J. (1987). Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma. Prostate, 11(3), 271-279.
DOI Scopus58 WoS56 Europe PMC42
1986 Horsfall, D. J., Tilley, W. D., Orell, S. R., Marshall, V. R., & Cant, E. L. M. K. (1986). Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. British Journal of Cancer, 53(1), 23-28.
DOI Scopus70 WoS82 Europe PMC54
1985 Tilley, W. D., Horsfall, D. J., Cant, E. L. M. K., & Marshall, V. R. (1985). Specific binding of oestradiol to guinea-pig prostate cytosol and nuclear fractions. Journal of Steroid Biochemistry, 22(6), 705-711.
DOI Scopus12 WoS12 Europe PMC5
1985 Tilley, W. D., Horsfall, D. J., McGee, M. A., Henderson, D. W., & Marshall, V. R. (1985). Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea-pig prostate. Journal of Steroid Biochemistry, 22(6), 713-719.
DOI Scopus25 WoS28 Europe PMC17
1982 Tilley, W. D., & Marshall, V. R. (1982). Steroid hormone receptors in the guinea-pig prostate: Effect of castration. Clinical and Experimental Pharmacology and Physiology, 9(5), 527-528.
1981 Tilley, W. D., Keightley, D. D., & Marshall, V. R. (1981). Properties of the cytoplasmic and nuclear oestrogen receptor in the guinea-pig prostate. Clinical and Experimental Pharmacology and Physiology, 8(4), 355-356.
1981 Tilley, W., Keightley, D., & Marshall, V. (1981). Oestrogen and androgen receptors in benign prostatic hyperplasia and carcinoma of the prostate. British Journal of Urology, 53(1), 74.
1980 Tilley, W. D., Keightley, D. D., & Marshall, V. R. (1980). Steroid hormone receptors in human benign prostatic hypertrophy (BPH). Clinical and Experimental Pharmacology and Physiology, 7(4), 442-443.
1980 Tilley, W. D., Keightley, D. D., & Marshall, V. R. (1980). Oestrogen and progesterone receptors in benign prostatic hyperplasia in humans. Journal of Steroid Biochemistry, 13(4), 395-399.
DOI Scopus27 WoS28 Europe PMC20
1978 Tilley, W. D., Keightley, D. D., & Cant, E. L. M. (1978). Inter-site variation of oestrogen receptors in human breast cancers. British Journal of Cancer, 38(4), 544-546.
DOI Scopus32 WoS43 Europe PMC26
1978 Keightley, D. D., Tilley, W. D., & Cant, E. L. M. (1978). Effect of snap freezing, dithiothreitol and storage on estimations of estrogen receptor sites. Clinica Chimica Acta, 88(2), 337-343.
DOI Scopus8 WoS9 Europe PMC4

Year Citation
2014 Moore, N., Centenera, M., Butler, L., Hickey, T., & Tilley, W. (2014). Androgens and the androgen receptor (AR). In E. Gelmann, C. Sawyers, & F. Rauscher (Eds.), Molecular oncology: Causes of cancer and targets for treatment (1 ed., pp. 378-391). Cambridge, United Kingdom: Cambridge University Press.
DOI
2013 Selth, L., Townley, S., Gillis, J., Tilley, W., & Butler, L. (2013). Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. In T. Ochiya (Ed.), Circulating MicroRNAs. Methods and Protocols (Vol. 1024, pp. 235-246). UK: Springer.
DOI Scopus3 Europe PMC3
2013 Selth, L. A., Townley, S. L., Gillis, J. L., Tilley, W. D., & Butler, L. M. (2013). Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. In Methods in Molecular Biology (pp. 235-246). Humana Press.
DOI
2009 Buchanan, G., Need, E., Bianco-Miotto, T., Greenberg, N., Scher, H., Centenera, M., . . . Tilley, W. (2009). Insights from AR gene mutations. In D. Tindall, & J. Mohler (Eds.), Androgen action in prostate cancer (pp. 207-240). Dordrecht, Netherlands: Springer.
DOI Scopus4 WoS4
2008 Beekman, K. W., Buchanan, G., Tilley, W. D., & Scher, H. I. (2008). Antiandrogen withdrawal syndromes: Pathophysiology and clinical implications. In Treatment Methods for Early and Advanced Prostate Cancer (pp. 317-325).
2006 Beekman, K., Buchanan, G., Tilley, W., & Scher, H. (2006). Antiandrogen withdrawal syndromes: pathophysiology and clinical implications. In R. S. Kirby, A. W. Partin, M. Feneley, & J. Kellogg Parsons (Eds.), Prostate cancer: principles and practice (pp. 979-988). London: Taylor & Francis.
2005 Beekman, K., Tilley, W., & Buchanan, G. (2005). Beyond first-line hormones: options for treatment of castration-resistant disease. In Comprehensive textbook of genitourinary oncology (pp. 330-340). Broadway, NSW: Lippincott Williams & Wilkins.
2003 Tilley, W., Buchanan, G., & Coetzee, G. (2003). Androgen receptor signaling in prostate cancer. In B. Henderson, B. Ponder, & R. Ross (Eds.), Hormones, genes, and cancer (pp. 288-315). 198 Madison Ave, New York, NY 10016: Oxford University Press.
- Antiandrogen withdrawal syndromes: Pathophysiology and clinical implications (n.d.).

Year Citation
2026 Peaston, A., Auricht, R., Hickey, T., Peters, M., MCLACHLAN, S., Birrell, S., & Tilley, W. (2026). First-in-Dog (FiDo) Cancer Initiative review. In Vet Science Week Proceedings 24-26 July 2026 Gold Coast Convention & Exhibition Centre (pp. 523). Gold Coast.
2026 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selt, L. A. (2026). CDK9 inhibition as a therapeutic strategy in advanced prostate cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. S64-S65). WILEY.
2025 Lawrence, M., Keerthikumar, S., Townley, S., Clark, A., Cuffe, G., Laven-Law, G., . . . Selth, L. (2025). Androgen receptor genomic structural rearrangements reshape the AR cistrome in castration-resistant prostate cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 21 (pp. 119). WILEY.
2020 Lim, E., Milioli, H. H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K. J., . . . Portman, N. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 110). WILEY.
2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2017 Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2013 Morel, K., Ormsby, R., Bezak, E., Tilley, W., Lawrence, M., & Sykes, P. (2013). Parthenolide as a selective radiosensitiser in the treatment and prevention of prostate cancer. In BJU International Vol. 112 (pp. 45). Melbourne: Wiley.
2012 Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research.
DOI
2009 Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.
2006 Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer.
1987 MARSHALL, V. R., TILLEY, W. D., & HORSFALL, D. J. (1987). LOCALIZATION AND REGULATION OF THE PROSTATIC ESTROGEN-RECEPTOR. In BRITISH JOURNAL OF UROLOGY Vol. 59 (pp. 182). BLACKWELL SCIENCE LTD.
1984 ELDER, D. D., HORSFALL, D. J., TILLEY, W. D., & MARSHALL, V. R. (1984). THE ROLE OF ESTROGEN IN PROSTATIC GROWTH. In BRITISH JOURNAL OF UROLOGY Vol. 56 (pp. 90). BLACKWELL SCIENCE LTD.
1983 HORSFALL, D. J., TILLEY, W. D., MARSHALL, V. R., & CANT, E. L. M. (1983). ENZYMATIC DISPERSAL TECHNIQUE FOR FLOW CYTOMETRIC QUANTITATION OF ESTROGEN-RECEPTOR IN HUMAN-BREAST TUMOR-CELLS. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 482-483). BLACKWELL SCIENCE.
1983 TILLEY, W. D., HORSFALL, D. J., & MARSHALL, V. R. (1983). ESTROGEN AND ANDROGEN RECEPTORS IN GUINEA-PIG PROSTRATE EPITHELIUM AND STROMA. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 439-440). BLACKWELL SCIENCE.
1981 TILLEY, W. D., KEIGHTLEY, D. D., & MARSHALL, V. R. (1981). ESTROGEN AND ANDROGEN RECEPTORS IN BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE. In BRITISH JOURNAL OF UROLOGY Vol. 53 (pp. 74). BLACKWELL SCIENCE LTD.
1979 TILLEY, W. D., KEIGHTLEY, D. D., & MARSHALL, V. R. (1979). HORMONE RECEPTORS IN BENIGN PROSTATIC HYPERPLASIA. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY Vol. 49 (pp. 147). BLACKWELL SCIENCE.
1978 KEIGHTLEY, D. D., TILLEY, W. D., & CANT, E. L. M. (1978). STORAGE OF TISSUE TO BE USED IN ESTROGEN-RECEPTOR ASSAYS. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY Vol. 48 (pp. 224). BLACKWELL SCIENCE.

Year Citation
2025 Haggstrom, L., Middleton, K., Segara, D., Ong, A., Bingham, J., Carson, E. -K., . . . Lim, E. (2025). The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer. Poster session presented at the meeting of Abstracts of the American Society of Clinical Oncology Annual Meeting (ASCO 2025), as published in Journal of Clinical Oncology. McCormick Place, Chicago, IL & Online: American Society of Clinical Oncology.
DOI
2025 Birrell, S., Tilley, W., Hickey, T., Dwyer, A., & Brewer, M. (2025). Real world study of the effect of T plus Ai on background parenchymal enhancement (BPE). Poster session presented at the meeting of BREAST CANCER RESEARCH AND TREATMENT. CA, San Francisco: SPRINGER.
2023 Freelander, A., Laven-Law, G., Eshraghi, L., Geetha, N., Somerville, P., Pickering, M., . . . Lim, E. (2023). Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models. Poster session presented at the meeting of CANCER RESEARCH. TX, San Antonio: AMER ASSOC CANCER RESEARCH.
DOI
2022 Freelander, A., Laven-Law, G., Eshraghi, L., Chia, K. M., Pickering, M., Yong, A., . . . Lim, E. (2022). Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers. Poster session presented at the meeting of CANCER RESEARCH. TX, San Antonio: AMER ASSOC CANCER RESEARCH.
DOI WoS3
2021 Portman, N., Milioli, H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K., . . . Lim, E. (2021). Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2021 Lau, B., Segara, D., Ong, A., Bingham, J., Kiely, B., Carson, E. -K., . . . Lim, E. (2021). Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
2020 Lim, E., Hickey, T. A., Selth, L. A., Chia, K. M., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2020). The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. TX, San Antonio: AMER ASSOC CANCER RESEARCH.
DOI
2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
WoS3
2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2019 Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. GA, Atlanta: AMER ASSOC CANCER RESEARCH.
DOI
2019 Winter, J. M., Mustafa, E. H., Wang, S., Selth, L. A., Hickey, T. E., & Tilley, W. D. (2019). Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells <i>in vitro</i>. Poster session presented at the meeting of CANCER RESEARCH. GA, Atlanta: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley.
2018 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology.
DOI
2018 Daniel, M. L., Hickey, T. E., Carroll, J. S., Tilley, W. D., Selth, L. A., & Dehm, S. M. (2018). Deciphering the regulome of androgen receptor variants in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI
2017 Tilley, W. (2017). Steroid receptor cross talk in breast cancer: molecular insights and therapeutic implications. Poster session presented at the meeting of Clinical Endocrinology. Broadbeach, Queensland: Wiley.
2017 Tilley, W. (2017). Steroid receptor RIMEs in breast and prostate cancer. Poster session presented at the meeting of Clinical Endocrinology. Broadbeach, Queensland: Wiley.
2016 Tarulli, G. A., Laven-Law, G., Tilley, W. D., & Hickey, T. E. (2016). Unraveling an identity for the androgen receptor-expressing mammary epithelial cell. Poster session presented at the meeting of Clinical Endocrinology. Adelaide: Wiley.
2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2016 Tilley, W. (2016). Targeting progesterone and androgen receptors to enhance er-target therapies in breast cancer. Poster session presented at the meeting of Asia-Pacific Journal of Clnical Oncology. Wiley.
2016 Asim, M., Massie, C., Warren, A., Luko, K., Chohan, B., Menon, S., . . . Neal, D. (2016). Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH.
DOI
2014 Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
2014 Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI WoS1
2014 Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia.
2014 Hickey, T. E., Robinson, J. L., Moore, N. L., Russell, R., Selth, L., Rueda, O., . . . Tilley, W. D. (2014). The androgen receptor restricts estrogen receptor Alpha DNA binding in breast cancer cells. Poster session presented at the meeting of Endocrine Reviews. Chicago: Endocrine Society.
2014 Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC.
2014 Oh, T. G., Bailey, P., Dray, E., Goode, J., Eriksson, N., Funder, J. W., . . . Muscat, G. E. (2014). Breast cancer and metastasis free survival are effected by PRMT2 and Rory; Expression: Understanding the Role of DNA Repair. Poster session presented at the meeting of Endocrine Reviews. Chicago: Endocrine Society.
2014 Ravindranathan, P., Tilley, W., & Raj, G. V. (2014). Rational targeting of the Androgen receptor interactome in prostate cancer. Poster session presented at the meeting of Cancer Research. San Diego, CA: American Association for Cancer Research.
DOI
2013 Sykes, P., Ormsby, R., Blyth, B., Bezak, E., Newman, M., Tilley, W., & Lawrence, M. (2013). Lack of a low-dose radiation adaptive response on prostate cancer progression in the TRAMP model. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013 Tilley, W., & Hickey, T. (2013). Androgen-receptor: A two-edge sword?. Poster session presented at the meeting of European Journal of Cancer. Amsterdam, Netherlands: Elsevier.
2013 Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013 Proctor, L. A., Hanson, A. R., Butler, M. S., Tilley, W. D., & Moore, N. L. (2013). Cyclin-dependent kinase 2 regulates androgen receptor activity in estrogen receptor negative breast cancer. Poster session presented at the meeting of Molecular Cancer Research. San Diego, CA: American Association for Cancer Research.
DOI WoS1
2013 Tilley, W. (2013). Androgens: role in aging & prostate cancer - non castrate and castrate resistant states. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2011 Bianco-Miotto, T., Chiam, K., Jindal, S., Ryan, N., Zulkifli, S., Moretta, S., . . . Owens, J. (2011). Early life exposure to a high fat diet results in histological and molecular changes in the rat prostate which are transmitted paternally to the second generation. Poster session presented at the meeting of Journal of Developmental Origins of Health and Disease. Portland, Oregon: Cambridge University Press.
2010 Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier.
DOI
2009 Jankovic-Karasoulos, T., Birrell, S. N., Cops, E. J., Jindal, S., Ochnik, A., Thomas, M., . . . Hickey, T. E. (2009). Evaluation of testosterone supplementation during anastrozole therapy in a breast explant model. Poster session presented at the meeting of Cancer Research. San Antonio, Texas: American Association for Cancer Research.
DOI
2009 Birrell, S. N., & Tilley, W. D. (2009). Testosterone undecanoate treatment reduces joint morbidities induced by anastrozole therapy in postmenopausal women with breast cancer: results of a double-blind, randomized phase ii trial. Poster session presented at the meeting of Cancer Research. San Antonio, Texas: American Association for Cancer Research.
DOI WoS3
2008 Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press.
DOI
2008 Hickey, T., Butler, M., Ricciardelli, C., Norman, R., & Tilley, W. (2008). Expression of small glutamine-rich tetratricopeptide repeat-containing protein alpha (alpha SGT), a novel regulator of androgen receptor (AR) activity, in the human ovary and fallopian tube. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press.
DOI WoS1
2006 Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research.

Year Citation
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Data from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Data from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI

Year Citation
2025 Mustafa, E., Laven-Law, G., Winter, J., Kikhtyak, Z., Bergeron, A., MacGrogan, G., . . . Hickey, T. (2025). The transcription factor AP-2β defines active enhancers conferring molecular apocrine cell identity in breast cancer.
DOI
2024 Heydarlou, H., Hodson, L., Dorraki, M., Hickey, T., Tilley, W., Smith, E., . . . Farajpour, A. (2024). A Deep Learning Approach for Classification of Fibroglandular Breast Density in Histology Images of Human Breast Tissue.
DOI

NHMRC Ideas Grant

APP1186647

2020-2023

$1,148,310

A combinatorial drug strategy to target lethal forms of breast cancer.

W.D. Tilley, E. Lim, R. Iggo, J. Carroll

NHMRC Project Grant

APP1145777

2018-2021

$998,754

Pushing AR toward better outcomes in breast and prostate cancers.

W.D. Tilley, T. Hickey, L. Selth, J. Carroll, E. Lim, W. Zwart, A. Joshua, C. Sweeney

NHMRC Project Grant  APP1138242

2018-2021

$799,440

A novel strategy for targeting castrate-resistant prostate cancer.

G. Risbridger, W.D. Tilley, L. Furic, S. Sandhu, A. Azad, L. Selth, M. Lawrence

Movember and National Breast Cancer Foundation, Australia

2018-2021

$2,958,714

Transforming endocrine therapy for breast and prostate cancer.

W.D. Tilley, G. Risbridger, J. Carroll, E. Lim, S. Clark, T. Hickey, L. Selth  

The Hospital Research Foundation, Australia

2018-2021

$375,000.00

Transforming therapy for breast and prostate cancer.

W.D. Tilley, T. Hickey, L. Selth

NHMRC Development Grant

APP1135682

2018-2020

$1,171,199

Development of a novel and highly selective CDK4/6 inhibitor for treating cancer.

S. Wang, R. Milne, W.D. Tilley, E. Lim

Cancer Research UK, Cambridge University

A23654

2018-2020

£193,783

PEARL Study: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer.

C. Palmieri, W.D. Tilley, S. Chauhan, C. Rawcliffe, J. Neoptolemos, J. Carroll, E. Lim

NHMRC Project Grant APP1121057

2017-2020

$959,423

Dual targeting of the Androgen Receptor for Effective and Durable Control of Lethal Prostate Cancer.

W.D. Tilley,  G. Risbridger,  G. Raj,  L. Selth,  J. Taylor,  A. Joshua

NHMRC Project Grant

APP1130077

2017-2020

$1,023,132

The clinical significance of sex hormone receptor crosstalk in ER+ breast cancer.

W.D. Tilley, J. Carroll, T. Hickey, E. Lim, L. Selth, E. Ebrahimie, S. Birrell, C. Palmieri, G. Greene, A. Bruna, C. Lange, F. Classens, N. Dean, F. Markowetz, A. Swarbrick

Cancer Council of NSW

2017-2019

$450,000

WinPro: Progesterone as an anticancer therapy in early breast cancer.

E. Lim, W.D. Tilley

Date Role Research Topic Program Degree Type Student Load Student Name
2024 Co-Supervisor Selective Androgen Receptor Modulators (SARMs) for the Treatment of Androgen Receptor positive (AR+) and Estrogen Receptor Positive (ER+) Breast Cancer. Doctor of Philosophy Doctorate Full Time Mr Manjit Rana
2023 Principal Supervisor Investigating the role of androgen receptors in bladder cancer Doctor of Philosophy Doctorate Full Time Mr Ahmed Faris Abdulridha Aldoghachi
2023 Co-Supervisor Role of Androgen Receptor Signalling in the Metastasis of Estrogen Receptor Positive Breast Cancer Doctor of Philosophy Doctorate Full Time Ms Dana Basem Mohamad Al Safadi

Date Role Research Topic Program Degree Type Student Load Student Name
2022 - 2025 Co-Supervisor Mechanistic Insights into Androgen and Progesterone Receptor Mediated Tumour Suppression in ER Positive Breast Cancer Doctor of Philosophy Doctorate Full Time Ms Maliha Wajahat .
2021 - 2023 Co-Supervisor Unlocking Insights from Complex Transcriptomic Data: Novel Bioinformatics Methods for Neurodegeneration and Cancer Studies Doctor of Philosophy Doctorate Full Time Miss Nora Liu
2021 - 2026 Principal Supervisor Insights into androgen receptor agonism as a therapeutic strategy to overcome endocrine resistance in ER-positive breast cancer Doctor of Philosophy Doctorate Full Time Mr Alex Adrian Pace
2019 - 2023 Co-Supervisor Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer Doctor of Philosophy Doctorate Full Time Ms Meiwen Danielle Fang
2017 - 2021 Co-Supervisor Role of the GATA3 Transcription Factor on AR Signalling in Breast Cancer Doctor of Philosophy Doctorate Full Time Mrs Leila Hosseinzadeh
2017 - 2021 Co-Supervisor Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Raj Kumar Shrestha
2017 - 2021 Co-Supervisor Development of a Novel Therapeutic Strategy for Estrogen Receptor Negative Breast Cancer Doctor of Philosophy Doctorate Full Time Mrs Ebtihal Hashem Mustafa
2017 - 2021 Co-Supervisor Extreme Activation of Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Mr Mohammadreza Alizadeh Ghodsi
2016 - 2020 Co-Supervisor The Role of MicroRNA-194 in Prostate Cancer Progression Doctor of Philosophy Doctorate Full Time Miss Rayzel Candida Fernandes
2010 - 2016 Co-Supervisor The Role of Estrogen Receptor and the Androgen Receptor in Human Breast Cancer Doctor of Philosophy Doctorate Part Time Mrs Shalini Jindal
2009 - 2013 Co-Supervisor Investigation into the Expression and Localisation of C-Kit and the Regulation of Kit Ligand Gene Expression in the Adult Human Ovary Doctor of Philosophy Doctorate Full Time Dr Astrud Tuck
2008 - 2012 Co-Supervisor The Molecular Actions of Medroxyprogesterone Acetate on Androgen Receptor Signalling and the Promotion of Breast Cancer Doctor of Philosophy Doctorate Full Time Miss Aleksandra Monica Ochnik
2008 - 2011 Co-Supervisor Characterisation of the Co-chaperone Small Glutamine-rich Tetratricopeptide Repeat containing Protein Alpha as a Regulator of Androgen Receptor Activity in Prostate Cancer Cells Doctor of Philosophy Doctorate Full Time Dr Andrew Trotta
2008 - 2012 Co-Supervisor The Role of Small Glutamine-Rich Tetratricopeptide Repeat Containing Protein Alpha in Female Reproductive Tissues Doctor of Philosophy Doctorate Full Time Ms Miriam Simone Butler
2007 - 2012 Co-Supervisor Mathematical Models of Cell Cycle Progression: Applications to Breast Cancer Cell Lines Doctor of Philosophy Doctorate Part Time Miss Kate Simms
2007 - 2015 Co-Supervisor Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Miss Sarah Carter
2006 - 2010 Co-Supervisor The Role of Epigenetic Modifications in Prostate Tumourigenesis Doctor of Philosophy Doctorate Full Time Ms Karen Huiqin Chiam
2004 - 2008 Co-Supervisor Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells Doctor of Philosophy Doctorate Part Time Dr Margaret Centenera
2004 - 2008 Co-Supervisor Androgen Signalling in Normal and Malignant Breast Epithelial Cells Doctor of Philosophy Doctorate Part Time Ms Amelia Peters
2004 - 2008 Co-Supervisor Androgens and Androgen Receptor Signalling in Men Doctor of Philosophy Doctorate Full Time Dr Elle Need
2003 - 2007 Principal Supervisor Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Deborah Marrocco
2002 - 2004 Co-Supervisor Versican: regulation, purification, and biological properties of a candidate prognostic indicator for breast cancer Doctor of Philosophy Doctorate Full Time Miss Supaporn Suwiwat
2002 - 2004 Principal Supervisor ANDROGEN SIGNALLING IN HUMAN BREAST CANCER CELLS Doctor of Philosophy Doctorate Full Time Dr Nicole Moore

Date Role Research Topic Location Program Supervision Type Student Load Student Name
2021 - ongoing Principal Supervisor Exploring the role of steroid receptors in ER+ breast cancer. University of Adelaide Doctor of Philosophy (Medical Science) Doctorate Full Time Alex Pace

Date Engagement Type Partner Name
2019 - ongoing Consultant Radius Health, Waltham, Massachusetts: Selective androgen receptor modulators (SARMs) and breast cancer program.

Date Title Type Institution Country
2008 - ongoing Advisory Editor Journal Review Endocrine-Related Cancer -
2008 - ongoing Editorial Board Journal Review Oncology Times -

Connect With Me

External Profiles

Other Links